AZD8529

Research use only, not for human use.

AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM.

AZD8529 is a novel potent, selective mGluR2 positive allosteric modulator with EC50 of 195 nM, does not produce any positive allosteric modulator responses for mGluR1 and 3-8 subtypes; potentiates agonist-induced activation of mGluR2 in the membrane-binding assay and in primate cortex, hippocampus and striatum; decreases nicotine self-administration at doses (0.3-3 mg/kg) in monkeys, also reduces nicotine priming- and cue-induced reinstatement of nicotine seeking, decreases nicotine-induced accumbens dopamine release in rats.Schizophrenia Phase 2 Discontinued.

AZD-8529 potentiates the effects of glutamate at mGluR2 with an EC50 of 195 nM.AZD-8529 does not elicit antagonist responses on mGluRs at 25 μM.

AZD-8529 (0.3-mg/kg, i.m.) reduces nicotine priming-induced and cue-induced reinstatement in squirrel monkeys. AZD-8529 (30 mg/kg; i.p.) decreases the increased extracellular dopamine induced by nicotine in accumbens shell of freely-moving rats. Animal Model:Sprague-Dawley rats Dosage:10 mg/kg, 30 mg/kg Administration:Intraperitoneal injection; 2 hours before nicotine injections Result:Decreased the increased extracellular dopamine induced by nicotine (0.4 mg/kg, s.c.) in accumbens shell of freely-moving rats.

AZD 8529

GPCR/G Protein

mGluR

mGluR

Neurological Disease

Schizophrenia

1092453-15-0

487.483

C24H24F3N5O3

>98% (HPLC)

In Vitro:?DMSO : 62.5 mg/mL (128.21 mM)

CC1=CC(=CC2=C1C(=O)N(C2)CC3=CC=C(C=C3)OC(F)(F)F)C4=NC(=NO4)CN5CCNCC5

2,3-Dihydro-7-methyl-5-[3-(1-piperazinylmethyl)-1,2,4-oxadiazol-5-yl]-2-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindol-1-one

(-20℃)

With Ice Pack

≥ 2 years